- Home
- DATS vs APLM Comparison
DATS vs APLM Comparison
Compare DATS & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- APLM
- Stock Information
- Founded
- DATS 2014
- APLM 2016
- Country
- DATS United States
- APLM United States
- Employees
- DATS N/A
- APLM N/A
- Industry
- DATS Computer Software: Prepackaged Software
- APLM Blank Checks
- Sector
- DATS Technology
- APLM Finance
- Exchange
- DATS Nasdaq
- APLM Nasdaq
- Market Cap
- DATS 9.5M
- APLM 7.7M
- IPO Year
- DATS 2021
- APLM N/A
- Fundamental
- Price
- DATS $2.79
- APLM $6.16
- Analyst Decision
- DATS
- APLM Strong Buy
- Analyst Count
- DATS 0
- APLM 2
- Target Price
- DATS N/A
- APLM $425.00
- AVG Volume (30 Days)
- DATS 8.0M
- APLM 42.6K
- Earning Date
- DATS 05-13-2025
- APLM 04-15-2025
- Dividend Yield
- DATS N/A
- APLM N/A
- EPS Growth
- DATS N/A
- APLM N/A
- EPS
- DATS N/A
- APLM N/A
- Revenue
- DATS $436.00
- APLM $2,101,000.00
- Revenue This Year
- DATS N/A
- APLM N/A
- Revenue Next Year
- DATS N/A
- APLM N/A
- P/E Ratio
- DATS N/A
- APLM N/A
- Revenue Growth
- DATS N/A
- APLM 70.54
- 52 Week Low
- DATS $1.01
- APLM $6.20
- 52 Week High
- DATS $9.34
- APLM $63.00
- Technical
- Relative Strength Index (RSI)
- DATS 51.75
- APLM 42.37
- Support Level
- DATS $2.92
- APLM $6.50
- Resistance Level
- DATS $3.39
- APLM $8.00
- Average True Range (ATR)
- DATS 0.60
- APLM 1.36
- MACD
- DATS 0.05
- APLM -0.22
- Stochastic Oscillator
- DATS 24.78
- APLM 5.93
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.